Press release from Companies

Publicerat: 2021-03-22 08:00:00

Redwood Pharma AB: Phase II results published in medical journal and Redwood Pharma to present poster at medical meeting

The results of Redwood Pharma's Phase II study of RP101 have now been published in the medical journal Advances in Therapy and will also be presented as a scientific poster presentation at the forthcoming annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).

In 2020, Redwood Pharma completed a Phase II clinical trial in Europe of RP101, the company's drug candidate for the treatment of chronic dry eye in post-menopausal women. The results have now been published in Advances in Therapy, an international scientific journal in clinical medicine. See link:

(https://link.springer.com/article/10.1007/s12325-021-01680-3)

The results of Redwood Pharma's Phase II trial of RP 101 will also be presented in a poster presentation at the upcoming virtual annual meeting of the US-based research organization Association for Research in Vision and Ophthalmology (www.arvo.org) on ??May 1-7. ARVO is one of the world's largest and most respected research organizations in the field of vision and eyes and has almost 11,000 researchers globally.

For further information
Martin Vidaeus – CEO, Phone: 070-232 29 29
Email: martin.vidaeus@redwoodpharma.com

About Redwood Pharma

Redwood Pharma develops ophthalmic products for unmet medical needs through novel approaches. In providing commercial partners and their customers with effective medical solutions, the Company is currently developing treatments for dry eye disease in various target patient populations. The RP101 program targets moderate-to-severe dry eye disease in post-menopausal women by delivering a low-dose estrogen therapy to the front of the eye. The RP501 program aims to treat milder forms of dry eye in a broader patient population including both men and women of all ages. For other potential drug substances and therapeutic areas, the Company can employ the IntelliGel drug delivery platform that enhances patient convenience by controlling dosing and potentially reducing the number of instillations per day and subsequent side-effects. Redwood Pharma leverages its strengths in early clinical development and aims to generate revenues through, among others, licensing agreements with companies that have capabilities to manufacture and sell medical products worldwide.

Redwood Pharma AB (publ) is listed on the Spotlight Stock Market (Ticker: REDW.ST, ISIN: SE008294789).

For more information visit: www.redwoodpharma.com

Läs mer hos Cision
Läs mer om Redwood Pharma AB

Prenumeration